April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Analysis of Multiple Chemokines and Growth Factors in the Vitreous of Patients With Branch Retinal Vein Occlusion
Author Affiliations & Notes
  • Y. Okunuki
    Ophthalmology, Tokyo Medical Univ Hospital, Tokyo, Japan
    Department of Ophthalmology, Hachiouji Medical Center of Tokyo Medical University, Tokyo, Japan
  • Y. Usui
    Ophthalmology, Tokyo Medical Univ Hospital, Tokyo, Japan
  • N. Katai
    Department of Ophthalmology, Hachiouji Medical Center of Tokyo Medical University, Tokyo, Japan
  • M. Takeuchi
    Ophthalmology, Tokyo Medical Univ Hospital, Tokyo, Japan
  • T. Kezuka
    Ophthalmology, Tokyo Medical Univ Hospital, Tokyo, Japan
  • Y. Wakabayashi
    Department of Ophthalmology, Hachiouji Medical Center of Tokyo Medical University, Tokyo, Japan
  • H. Goto
    Ophthalmology, Tokyo Medical Univ Hospital, Tokyo, Japan
  • Footnotes
    Commercial Relationships  Y. Okunuki, None; Y. Usui, None; N. Katai, None; M. Takeuchi, None; T. Kezuka, None; Y. Wakabayashi, None; H. Goto, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5397. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Okunuki, Y. Usui, N. Katai, M. Takeuchi, T. Kezuka, Y. Wakabayashi, H. Goto; Analysis of Multiple Chemokines and Growth Factors in the Vitreous of Patients With Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5397.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To analyze intravitreous concentrations of multiple chemokines and growth factors in patients with branch retinal vein occlusion (BRVO) and to compare the results with those of diabetic retinopathy (DR).

Methods: : Eighteen BRVO (age 67.8±6.2, 9 men and 9 female), 14 DR (age 65.9±3.5, 8 men and 6 female), and 15 control subjects (age 65.3±8.7, 7 men and 8 female) were enrolled in this study. Among BRVO and DR patients, those with macular edema but no vitreous hemorrhage and new vessel were selected. Patients with a history of previous ocular surgery were excluded. Control subjects consisted of 10 patients with macular hole and 5 with epiretinal membrane. Vitreous and blood samples were obtained at the time of vitrectomy. Vitreous and serum concentrations of VEGF, IL-8, MCP-1, Mig, IP-10, basic FGF, GM-CSF, and RANTES were quantified using a FACS Caliber flow cytometer.

Results: : VEGF, IL-8, MCP-1, Mig, IP-10 were detected in the vitreous of BRVO patients and the concentrations were 160.0, 46.9, 1596.0, 90.1, and 155.2 pg/ml, respectively. IL-8 concentration in the vitreous was significantly higher in BRVO patients compared with DR patients (24.5 pg/ml) (p<0.05). In BRVO patients, vitreous concentration of IL-8 correlated significantly with vitreous concentrations of VEGF (p<0.0001), MCP-1 (p<0.0001), Mig (p<0.05), and IP-10 (p<0.01). All the factors detectable in the vitreous were higher in BRVO patients compared with controls. In BRVO patients, vitreous concentrations of VEGF and MCP-1 were higher than serum concentrations, but vitreous concentrations of IL-8, Mig, and IP-10 were not significantly different from serum concentrations.

Conclusions: : Intravitreous VEGF, MCP-1, Mig, and IP-10 and especially IL-8 may contribute to the pathogenesis of BRVO.

Keywords: vascular occlusion/vascular occlusive disease • vitreous • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×